Know What Is Chromosomal Microarray Testing During Pregnancy

Chromosomal microarray testing during pregnancy is an advanced genetic test.

It can detect small chromosome changes that may not be identified by standard prenatal testing.

Pregnancy is filled with exciting milestones, from hearing your baby’s heartbeat for the first time to watching tiny movements during an ultrasound scan.

Alongside these joyful moments, modern prenatal care also offers advanced genetic tests that can provide valuable insights into your baby’s health before birth.

One such test is Chromosomal Microarray Analysis (CMA), a diagnostic tool that has transformed the way healthcare professionals investigate certain fetal genetic conditions.

For many parents, hearing terms like chromosomal abnormality, microarray, or copy number variation can be overwhelming.

It is completely understandable.

Genetic testing has evolved rapidly over the last decade, and with more testing options available than ever before, knowing which test does what can be confusing.

As a women’s health physiotherapist,

I often meet expecting mothers who have been referred for additional prenatal investigations after an ultrasound finding or because of a previous pregnancy history.

While physiotherapists do not perform genetic testing, we play an important role in supporting women throughout pregnancy by helping them:

manage physical discomfort, reduce stress, improve mobility, and navigate emotionally challenging situations alongside the wider maternity care team.

The purpose of this article is not to create unnecessary anxiety but to help you understand :

what Chromosomal Microarray Testing is, when it may be recommended, what it can and cannot detect, and how it fits into modern pregnancy care.

By understanding the facts, you can have more informed conversations with your obstetrician and genetic counsellor if this test is ever recommended.

At a Glance

Feature	Chromosomal Microarray Testing in Pregnancy (CMA)
Purpose	Detects tiny chromosomal gains and losses (copy number variations)
Sample Required	CVS or Amniotic Fluid
Test Type	Diagnostic
Detects Down Syndrome	Yes
Detects Microdeletion Syndromes	Yes
Detects Balanced Translocations	No
Detects Single Gene Disorders	No
Recommended When	Structural abnormalities, abnormal prenatal findings, selected high-risk pregnancies

What Is Chromosomal Microarray Testing During Pregnancy?

Chromosomal Microarray Analysis or testing, commonly called CMA, is a laboratory technique that examines a baby’s chromosomes during pregnancy at a much higher resolution than conventional chromosome analysis.

Every person inherits 46 chromosomes, arranged in 23 pairs.

These chromosomes contain thousands of genes responsible for growth, development, and normal body function.

Sometimes, a tiny section of a chromosome may be missing (called a deletion) or duplicated (called a duplication).

These changes may affect fetal development and can be associated with intellectual disability, developmental delay, congenital anomalies, or certain genetic syndromes.

Unlike conventional karyotyping, which identifies only relatively large chromosomal changes, CMA can detect much smaller alterations known as submicroscopic copy number variations (CNVs).

Think of it this way.

If conventional karyotyping is like viewing a city from an airplane, chromosomal microarray is like using satellite imaging to zoom in and identify much smaller details that were previously invisible.

This improved resolution is one of the biggest reasons why CMA has become an important diagnostic tool in prenatal medicine.

Recent reviews continue to support CMA as a first-line diagnostic technique in pregnancies where fetal structural abnormalities are identified because of its higher detection rate compared with conventional chromosome analysis. (Liu et al. 2022).

How Does Chromosomal Microarray Analysis Work?

Unlike blood tests that screen for pregnancy hormones, CMA analyses fetal DNA collected through an invasive diagnostic procedure.

The DNA sample usually comes from:

Chorionic Villus Sampling (CVS)

CVS is generally performed between 10 and 13 weeks of pregnancy.

A small sample of placental tissue is collected and sent to the laboratory for genetic analysis.

Amniocentesis

Amniocentesis is usually performed after 15 weeks of pregnancy.

During the procedure, a small amount of amniotic fluid containing fetal cells is collected using a fine needle under ultrasound guidance.

Once the laboratory receives the fetal DNA, sophisticated technology compares thousands of chromosome regions against a normal reference genome.

Instead of looking only for missing or extra chromosomes, the test searches for very small gains or losses of genetic material across the entire genome.

This genome-wide approach allows clinicians to identify abnormalities that would often remain undetected using traditional chromosome analysis.

Why Has Chromosomal Microarray Become So Important?

One of the biggest advances in prenatal genetics has been the ability to detect clinically important chromosome changes that were previously invisible.

Large multicentre research involving more than 4,400 pregnancies demonstrated that chromosomal microarray identified all chromosomal abnormalities detected by conventional karyotyping,

while also identifying additional clinically significant abnormalities in pregnancies where standard chromosome analysis appeared normal.

Among fetuses with structural abnormalities identified on ultrasound, CMA detected additional clinically relevant findings in approximately 6% of pregnancies beyond conventional karyotyping. (Wapner et al. 2012).

For expecting parents, this means that a normal karyotype does not always rule out every clinically important chromosomal condition.

When Is Chromosomal Microarray Testing Recommended During Pregnancy?

Chromosomal Microarray Testing is not recommended for every pregnancy.

Instead, healthcare providers usually recommend it when there is a higher chance of finding a chromosomal abnormality.

Common situations include:

Structural Abnormalities Detected on Ultrasound

This is one of the most common reasons for recommending CMA.

Examples include:

• congenital heart defects
• brain abnormalities
• cleft lip or palate
• kidney abnormalities
• skeletal abnormalities
• abdominal wall defects

When these findings are present, CMA provides additional genetic information that may influence diagnosis, prognosis, and pregnancy counselling.

A systematic review found that chromosomal microarray provides an additional diagnostic yield beyond conventional karyotyping in pregnancies with fetal structural abnormalities, supporting its role in these clinical situations. (Hillman et al. 2013).

Increased Nuchal Translucency

An increased nuchal translucency measurement during the first-trimester ultrasound may indicate a higher risk of chromosomal or genetic conditions.

If invasive prenatal testing is performed, CMA is often considered because of its improved diagnostic capability.

Previous Pregnancy with a Chromosomal Abnormality

Couples who previously experienced a pregnancy affected by a chromosomal disorder may be offered diagnostic testing in future pregnancies depending on their individual circumstances.

One Parent Has a Chromosomal Rearrangement

If one biological parent carries a balanced chromosomal rearrangement, genetic counselling and diagnostic testing may be recommended to evaluate the fetus.

A Lesser-Known Fact

Many people assume that a normal ultrasound means the baby’s chromosomes are completely normal.

Unfortunately, this is not always true.

Some chromosomal changes are too small to produce obvious structural abnormalities during routine ultrasound examinations.

Others may affect brain development or future learning without causing visible physical differences before birth.

This is one reason why CMA has become an important diagnostic investigation in carefully selected pregnancies.

It provides genetic information that imaging alone cannot always reveal.

Recent reviews continue to emphasize that CMA complements, rather than replaces, detailed prenatal ultrasound by detecting clinically significant copy number variants that may not be apparent on imaging (Liu et al. 2022).

What Conditions Can Chromosomal Microarray Testing Detect?

One of the biggest advantages of Chromosomal Microarray Analysis (CMA) is its ability to detect copy number variations (CNVs),

which are tiny missing (deletions) or extra (duplications) pieces of DNA that may affect a baby’s growth and development.

These genetic changes are often too small to be seen using conventional karyotyping.

Although not every CNV causes health problems, some are associated with well-recognised genetic conditions and congenital abnormalities.

Down Syndrome and Other Common Chromosomal Disorders

CMA can detect common chromosome abnormalities, including:

• Down syndrome (Trisomy 21)
• Edwards syndrome (Trisomy 18)
• Patau syndrome (Trisomy 13)
• Turner syndrome
• Other chromosome gains or losses

However, it is important to remember that CMA is not primarily performed to diagnose these conditions.

Conventional prenatal screening and diagnostic tests can also identify many of them.

The real strength of Chromosomal Microarray Testing lies in detecting smaller chromosomal changes that standard chromosome analysis may overlook during pregnancy.

Microdeletion and Microduplication Syndromes

These conditions occur when very small pieces of chromosomes are either missing or duplicated.

Examples include:

• 22q11.2 Deletion Syndrome (DiGeorge syndrome)
• Williams syndrome
• Smith-Magenis syndrome
• 1p36 deletion syndrome
• Prader-Willi syndrome
• Angelman syndrome (when caused by specific chromosomal deletions)

Many of these conditions can affect learning, growth, heart development, immunity, or behaviour.

Because the affected chromosome segments are often extremely small, conventional karyotyping may fail to detect them.

Clinically Significant Copy Number Variations

Not every chromosome change fits into a named syndrome.

Sometimes CMA identifies a pathogenic copy number variation that explains abnormal ultrasound findings or developmental concerns, even when the change has not yet been associated with a specific syndrome.

Large clinical studies have shown that CMA identifies additional clinically significant genomic abnormalities beyond conventional karyotyping, particularly in pregnancies with fetal structural anomalies (Levy et al. 2019).

What Chromosomal Microarray Testing Cannot Detect

Despite being an advanced diagnostic test, CMA has limitations.

Understanding these limitations helps parents develop realistic expectations and appreciate why healthcare providers sometimes recommend additional testing.

Single-Gene Disorders

CMA does not detect most conditions caused by changes in a single gene.

Examples include:

• Cystic fibrosis
• Sickle cell disease
• Spinal muscular atrophy
• Duchenne muscular dystrophy

These conditions usually require different types of genetic testing.

Balanced Chromosomal Rearrangements

Sometimes pieces of chromosomes exchange places without any gain or loss of genetic material.

These are called balanced translocations.

Because no DNA is missing or duplicated, CMA may not identify these rearrangements even though they can influence future pregnancies.

Low-Level Mosaicism

In some pregnancies, only a small proportion of fetal cells carry a chromosomal abnormality.

Very low levels of mosaicism may not always be detected by CMA, depending on the proportion of affected cells and the testing platform used.

Many Multifactorial Conditions

Conditions such as:

• autism spectrum disorder
• attention-deficit/hyperactivity disorder (ADHD)
• cerebral palsy
• many intellectual disabilities

often result from complex interactions between multiple genes and environmental factors. CMA cannot predict whether a child will develop these conditions in the future.

Chromosomal Microarray vs Conventional Karyotyping

Parents are often surprised that both tests analyse chromosomes but provide different levels of information.

Think of conventional karyotyping as looking at a road map from a distance.

Now imagine zooming in with high-resolution satellite imaging.

That is similar to what CMA offers.

Feature	Chromosomal Microarray	Karyotyping
Detects large chromosome abnormalities	✅	✅
Detects small deletions and duplications	✅	❌
Detects balanced translocations	❌	✅
Resolution	High	Lower
Diagnostic test	✅	✅

A systematic review concluded that CMA provides a higher diagnostic yield than conventional karyotyping, particularly when fetal structural abnormalities are identified during pregnancy (Hillman et al. 2013).

Chromosomal Microarray vs NIPT

These two tests are commonly confused, but they serve very different purposes.

Chromosomal Microarray	NIPT
Diagnostic test	Screening test
Requires CVS or amniocentesis	Maternal blood sample
Analyses fetal DNA directly	Analyses placental DNA fragments in maternal blood
Confirms chromosomal abnormalities	Estimates the likelihood of certain abnormalities
Can detect many clinically significant CNVs	Primarily screens for common chromosome abnormalities

A helpful way to remember this is:

NIPT estimates risk. CMA confirms diagnosis.

Because NIPT is a screening test, abnormal results generally require confirmation using diagnostic testing such as CVS or amniocentesis with chromosomal microarray.

Chromosomal Microarray vs CVS

This comparison often causes confusion because these terms describe different parts of the testing process.

CVS is the procedure.

Chromosomal microarray is the laboratory test.

During CVS, a small placental sample is collected.

That sample can then be analysed using:

• chromosomal microarray
• conventional karyotyping
• targeted genetic testing
• other specialised laboratory investigations

In other words, CVS is how the sample is obtained, while CMA is how the DNA is analysed.

Chromosomal Microarray vs Amniocentesis

The same principle applies here.

Amniocentesis is another method of obtaining fetal cells.

Those cells may subsequently undergo:

• chromosomal microarray analysis
• karyotyping
• molecular genetic testing
• additional laboratory analysis depending on the clinical indication

Therefore, amniocentesis and CMA are not competing tests. They work together.

Chromosomal Microarray vs Whole Exome Sequencing

Whole Exome Sequencing (WES) is one of the newest advances in prenatal genetics.

Unlike CMA, which detects missing or duplicated chromosome segments, WES examines the protein-coding regions of thousands of individual genes.

Chromosomal Microarray	Whole Exome Sequencing
Detects copy number variations	Detects gene variants
Excellent for chromosome gains and losses	Excellent for single-gene disorders
Widely used in prenatal diagnosis	Usually reserved for selected complex cases
Faster interpretation	Often more complex interpretation

Rather than replacing one another, CMA and WES are increasingly viewed as complementary tools.

In carefully selected pregnancies with major fetal anomalies and a normal CMA result, WES may provide an additional diagnosis when a single-gene disorder is suspected.

Real-Life Scenarios: When Doctors Recommend Chromosomal Microarray Testing

Understanding real clinical situations can make the role of CMA much clearer.

Scenario 1: An Unexpected Finding During the Anatomy Scan

A woman attends her routine 20-week ultrasound.

The sonographer identifies a congenital heart defect.

Although the pregnancy had a low-risk NIPT result, the obstetrician recommends amniocentesis with Chromosomal Microarray Testing;

because some chromosomal microdeletions are associated with heart abnormalities and would not necessarily be detected by routine screening.

Scenario 2: Increased Nuchal Translucency

During the first-trimester scan, the baby’s nuchal translucency measurement is significantly increased.

Even if no other abnormalities are seen, diagnostic testing with CMA may be offered because certain chromosomal abnormalities occur more frequently in these pregnancies.

Scenario 3: Multiple Structural Abnormalities

An ultrasound identifies abnormalities involving the kidneys, heart, and limbs.

Rather than relying solely on conventional chromosome analysis, the fetal medicine specialist recommends CMA because it has a higher chance of identifying clinically important genomic changes.

Large cohort studies continue to support combining careful ultrasound assessment with CMA in pregnancies involving fetal anomalies to improve diagnostic accuracy. (Wang et al. 2022).

Scenario 4: Previous Pregnancy Affected by a Chromosomal Disorder

A couple previously experienced a pregnancy complicated by a chromosomal abnormality.

During a subsequent pregnancy, they choose diagnostic testing early to obtain more detailed genetic information and reduce uncertainty.

Scenario 5: A Parent Has a Balanced Chromosomal Rearrangement

One prospective parent is known to carry a balanced chromosomal rearrangement.

Following genetic counselling, invasive prenatal testing may be recommended to better understand whether the fetus has inherited an unbalanced chromosomal change.

A Lesser-Known Fact

Many people believe that a low-risk NIPT result means all genetic conditions have been ruled out.

This is a common misconception.

NIPT is highly effective for screening common chromosome abnormalities, but it does not detect every clinically significant chromosomal change.

In selected pregnancies, especially when ultrasound abnormalities are present, diagnostic tests such as CMA can identify additional clinically important findings that screening tests may miss.

Understanding Your Chromosomal Microarray Test Results

Waiting for the results of any prenatal genetic test can be emotionally challenging.

It is natural to feel anxious, especially if the test was recommended because of an unexpected ultrasound finding.

One of the most important things to remember is that a Chromosomal Microarray Analysis (CMA) result is not simply “normal” or “abnormal.”

Some results are straightforward, while others require careful interpretation by a clinical geneticist or genetic counsellor.

A Normal Result

A normal CMA result means that no clinically significant chromosomal gains or losses were identified within the limits of the test.

This can be reassuring, particularly if the test was performed because of an abnormal screening result.

However, a normal CMA does not guarantee that a baby has no genetic condition.

Some disorders are caused by single-gene variants, balanced chromosomal rearrangements, or genetic mechanisms that CMA cannot detect.

Recent reviews emphasize that while CMA is one of the most powerful prenatal diagnostic tools available,

it has defined technical limitations and should be interpreted alongside ultrasound findings, family history, and other clinical information.

A Pathogenic Finding

Sometimes CMA identifies a pathogenic copy number variation, meaning there is strong scientific evidence that the detected chromosomal change is associated with a genetic disorder.

Depending on the specific finding, your healthcare team may discuss:

• the condition identified
• expected pregnancy outcomes
• possible medical complications
• additional imaging
• specialist referrals
• delivery planning
• newborn care

Receiving this information before birth allows families and healthcare professionals to prepare more effectively for the baby’s medical needs.

Variant of Uncertain Significance (VUS)

One of the most misunderstood CMA results is a Variant of Uncertain Significance (VUS).

A VUS means that a chromosomal change has been identified, but current scientific evidence is insufficient to determine whether it is harmless or disease-causing.

This can understandably create uncertainty for families.

Fortunately, many VUS findings become better understood over time as researchers gather more genetic data.

Your genetic counsellor may recommend:

• parental genetic testing
• review of family history
• additional imaging
• follow-up after birth if appropriate

Studies discussing prenatal CMA consistently highlight that careful pre-test and post-test genetic counselling is essential because variants of uncertain significance require expert interpretation and individualized discussion (Allen et al. 2017).

Benefits of Chromosomal Microarray Testing

CMA has become an important part of prenatal diagnosis because it offers several advantages over conventional chromosome analysis.

Higher Diagnostic Resolution

The biggest advantage is its ability to detect very small chromosomal deletions and duplications that cannot be identified using standard karyotyping.

This additional resolution improves the likelihood of identifying a genetic explanation for certain fetal abnormalities.

Better Information for Pregnancy Planning

An accurate diagnosis helps healthcare professionals:

• explain ultrasound findings
• estimate possible outcomes
• coordinate specialist care
• prepare delivery plans
• arrange neonatal support if required

For many families, having more information before birth reduces uncertainty and improves shared decision-making.

Improved Genetic Counselling

A confirmed diagnosis also allows genetic counsellors to explain:

• recurrence risk
• future pregnancy planning
• inheritance patterns
• available reproductive options

Large clinical studies continue to support CMA as an important diagnostic tool because it increases the detection of clinically significant chromosomal abnormalities compared with conventional cytogenetic analysis. (Shaffer et al. 2013).

Limitations of Chromosomal Microarray Testing

Although CMA is highly advanced, it is not a perfect test.

Understanding what it cannot do is just as important as understanding its strengths.

It Cannot Detect Every Genetic Disorder

Some inherited conditions result from:

• single-gene mutations
• balanced chromosome rearrangements
• mitochondrial disorders
• epigenetic changes

These usually require different forms of genetic testing.

Some Findings May Never Be Fully Explained

Occasionally, CMA identifies a rare chromosomal variation that has not been studied enough to determine its clinical significance.

This uncertainty can be emotionally difficult for parents, highlighting the importance of expert counselling.

CMA Does Not Predict a Child’s Future Abilities

Another common misconception is that CMA can predict intelligence, personality, learning ability, or future health.

It cannot.

Even when a chromosomal change is identified, the severity of symptoms often varies considerably between individuals.

A Lesser-Known Fact

Many people assume genetic testing always provides clear answers.

In reality, genetics is continually evolving.

A chromosomal change classified as a Variant of Uncertain Significance today may be reclassified in the future as either benign or pathogenic as more scientific evidence becomes available.

This is one reason why laboratories periodically update their interpretation guidelines and why maintaining communication with your healthcare provider is valuable if new information emerges.

The Physiotherapist’s Perspective

Learning that additional prenatal testing is needed can be emotionally exhausting.

Many women describe feeling overwhelmed while waiting for appointments, test results, or specialist consultations.

Although physiotherapists are not involved in interpreting genetic results, we play an important role in supporting physical and emotional wellbeing throughout pregnancy.

Our goal is to help women remain as healthy, active, and confident as possible while receiving appropriate obstetric care.

Supporting Safe Physical Activity

Unless advised otherwise by the obstetric team, maintaining appropriate physical activity during pregnancy offers many benefits.

Individualised exercise programmes may help:

• reduce back pain
• improve posture
• maintain cardiovascular fitness
• reduce fatigue
• support emotional wellbeing

Managing Pregnancy-Related Pain

Stress often increases muscle tension, particularly around the neck, shoulders, lower back, and pelvis.

Physiotherapy helps women manage these common discomforts through:

• posture education
• gentle strengthening
• movement modification
• breathing exercises
• manual therapy when appropriate

Pelvic Floor Preparation

Pelvic floor muscle training remains beneficial for many pregnant women regardless of whether additional prenatal investigations are being performed.

Learning correct pelvic floor activation before birth may improve confidence and support postpartum recovery.

Questions to Ask Your Healthcare Provider

If Chromosomal Microarray Analysis has been recommended, consider asking:

• Why is CMA being recommended in my pregnancy?
• What abnormalities are you looking for?
• How is CMA different from karyotyping?
• Will I need CVS or amniocentesis?
• What happens if the results are uncertain?
• Should my partner or I undergo additional testing?
• Will I meet with a genetic counsellor?
• How could the results affect pregnancy management?

Preparing these questions before your appointment can help you better understand the purpose of testing and make informed decisions.

Conclusion

Chromosomal Microarray Analysis has significantly improved prenatal diagnosis by identifying chromosomal changes that conventional testing may miss.

When recommended, it can provide valuable information to help families and healthcare professionals make informed decisions about pregnancy care.

Although receiving genetic testing can feel overwhelming, understanding the purpose, benefits, and limitations of CMA allows parents to approach the process with greater confidence.

Combined with expert obstetric care, genetic counselling, and supportive services such as physiotherapy, informed prenatal care empowers families to prepare for the healthiest possible pregnancy journey.

Stay tuned with us for more health related topics.

Follow us on LinkedIn and Instagram for more.

Medical Disclaimer!

This article has been reviewed and written under the guidance of our Head Physiotherapist, Dr. Kruti Raj (PT, MUHS,CPT,CMPT). The information shared is intended for educational purposes only and should not be considered a substitute for personalized medical advice, diagnosis, or treatment.

Please consult us or any other qualified healthcare professional before beginning any exercise program, especially if you are experiencing pain, recovering from injury, or managing a medical condition.